A randomized, placebo-controlled, double-blind, parallel group, multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 3934 administered orally in the correction of anemia in pre-dialysis subjects with chronic kidney disease not currently treated with erythropoiesis-stimulating agent in Europe and Asia Pacific
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Molidustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms DIALOGUE 1
- Sponsors Bayer HealthCare
- 10 Jan 2020 Results (N=42), assessing drug-drug interaction of Molidustat with iron and calcium supplements in patients with anemia as a result of chronic kidney disease, published in the European Journal of Clinical Pharmacology
- 01 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.